Amniotic and Placental-Derived Product Injections and/or Applications for Musculoskeletal Indications, Non-Wound
JE · Effective Nov 12, 2023
11 active Medicare policies list M19.93, and 10 commercial payer policies list it. See each policy's status for the code and its official source. Listing a code is not a coverage decision: read each policy’s source for the requirements that apply.
Free account. Policy pages stay open to everyone.
JE · Effective Nov 12, 2023
JF · Effective Nov 12, 2023
JJ · Effective Apr 30, 2023
JM · Effective Apr 30, 2023
National · Effective Oct 1, 2026
National · Effective Oct 1, 2026
J6 · Effective Oct 1, 2026
10 policies from 2 payers
Summary of the payer’s published policy. Not a coverage determination — confirm with the payer before submitting.
| Policy | Effective | Status of M19.93 |
|---|---|---|
| Anesthetic and Antiemetic Infusion Pumps | Aug 31, 2023 | Covered |
| Autologous Chondrocyte Implantation | Nov 20, 2023 | Covered |
| Blood and Adipose Tissue Derived Products for Selected Indications | Oct 26, 2023 | Covered |
| Bortezomib Products | Feb 2, 2024 | Covered |
| Chiropractic Services | Mar 23, 2023 | Covered |
| Infrared Therapy | Sep 8, 2023 | Covered |
National · Effective Oct 1, 2025
J5 · Effective Oct 1, 2026
J9 · Effective Jan 1, 2026
JL · Effective Jan 1, 2026
| Pulsed Electromagnetic Stimulation | Mar 14, 2023 | Covered |
|---|
| Thermography | Mar 15, 2023 | Covered |
|---|
| Viscosupplementation | Jan 1, 2024 | Covered |
|---|
| Policy | Effective | Status of M19.93 |
|---|---|---|
| Therapeutic use of Stem Cells, Blood and Bone Marrow Products | Oct 1, 2026 | Not covered |